<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5184">
  <stage>Registered</stage>
  <submitdate>29/07/2015</submitdate>
  <approvaldate>29/07/2015</approvaldate>
  <nctid>NCT02525094</nctid>
  <trial_identification>
    <studytitle>Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis</studytitle>
    <scientifictitle>A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis</scientifictitle>
    <utrn />
    <trialacronym>ALLEVIAD</trialacronym>
    <secondaryid>D5240C00001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atopic Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - MEDI9929
Other interventions - Placebo

Experimental: MEDI9929 - Subcutaneous (under the skin) injections administered on Day 1 to week 10

Placebo Comparator: Placebo - Subcutaneous (under the skin) injections administered on Day 1 to week 10


Other interventions: MEDI9929
Subcutaneous (under the skin) injections administered on Day 1, weeks 2, 4, 6, 8, 10.

Other interventions: Placebo
Subcutaneous (under the skin) injections administered on Day 1, weeks 2, 4, 6, 8, 10.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy as measured by fifty percent reduction from baseline in the Eczema Area and Severity Index (EASI 50) - Fifty percent reduction from baseline in the Eczema Area and Severity Index (EASI 50) as measured at week 12 for MEDI9929 as compared to Placebo</outcome>
      <timepoint>Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by the Investigator's Global Assessment (IGA) score - IGA score of 0 (clear) or 1 (almost clear) with at least a 2-grade reduction from baseline score for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by seventy-five percent reduction from baseline in the Eczema Area and Severity Index (EASI 75) - Seventy-five percent reduction from baseline in EASI (EASI 75) for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by the change from baseline in the Scoring of Atopic Dermatitis (SCORAD) - Absolute change from baseline in Scoring of Atopic Dermatitis (SCORAD) for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by fifty percent reduction from baseline in the Scoring of Atopic Dermatitis (SCORAD 50) - Fifty percent reduction from baseline in SCORAD (SCORAD 50) for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by seventy-five percent reduction from baseline in the Scoring of Atopic Dermatitis (SCORAD 75) - Seventy-five percent reduction from baseline in SCORAD (SCORAD 75) for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by the Pruritus Numeric Rating Scale (NRS) - The absolute change from baseline in the Pruritus Numeric Rating Scale (NRS) for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by the 5-D Pruritus score - The absolute change from baseline in 5-D Pruritus score for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety profile as measured by adverse events (AEs) (including adverse events of special interest (AESIs)), vital signs, physical examination, 12-lead electrocardiograms, clinical laboratory tests (hematology, clinical chemistry, urinalysis) - Using adverse events (AEs) (including adverse events of special interest (AESIs)), vital signs, physical examination, 12-lead electrocardiograms, clinical laboratory tests (hematology, clinical chemistry, urinalysis)</outcome>
      <timepoint>Weeks 0-22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics as measured by MEDI9929 serum concentrations. - Using MedI9929 concentration determination on serum only</outcome>
      <timepoint>Weeks 0-22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity as measured by the incidence rate of positive antibodies to MEDI9929 - Using anti-drug antibodies (a measure of the body's immune response to the drug)</outcome>
      <timepoint>Week 0-22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by the absolute change from baseline in the Eczema Area and Severity Index (EASI) - The absolute change from baseline in EASI for MEDI9929 as compared to Placebo</outcome>
      <timepoint>22 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  AD meeting Hanifin and Rajka criteria

          -  Age 18-75 years inclusive at screening

          -  Atopic dermatitis that affects greater than/equal to 10% body surface area

          -  Moderate to severe AD

          -  Effective birth control in line with protocol details</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis

          -  Hepatitis B, C or HIV

          -  Pregnant or breastfeeding

          -  History of anaphylaxis following any biologic therapy

          -  History of clinically significant infections within 4 weeks prior to Visit 3

          -  Diagnosis of helminth parasitic infection within 6 months to screening

          -  History of Cancer except basal cell

          -  Receipt of any marketed or investigational biologic agent within 4 months to visit 3

          -  Any clinically relevant abnormal finding

          -  Major surgery within 8 weeks prior to Visit 1</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>155</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - ACT</hospital>
    <hospital>Research Site - Liverpool</hospital>
    <hospital>Research Site - Woolloongabba</hospital>
    <postcode> - ACT</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt/Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Münster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pécs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szombathely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedImmune LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Amgen</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02525094</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eric Simpson, MD</name>
      <address>Oregon Health and Science University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>